These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25437185)

  • 1. Conference report from the International Congress on Infectious Diseases 2014: Part One. 16th International Congress on Infectious Diseases, Cape Town, South Africa 2-5 April 2014.
    McLoughlin H
    Future Microbiol; 2014; 9(11):1239-41. PubMed ID: 25437185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conference report from International Congress on Infectious Diseases 2014: part 2.
    McLoughlin H
    Future Microbiol; 2014; 9(12):1299-301. PubMed ID: 25517896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside.
    Beardsley J; Halliday CL; Chen SC; Sorrell TC
    Future Microbiol; 2018 Aug; 13(10):1175-1191. PubMed ID: 30113223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation.
    Sanglard D; Coste A; Ferrari S
    FEMS Yeast Res; 2009 Oct; 9(7):1029-50. PubMed ID: 19799636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meeting the challenge of invasive fungal infections: part 1.
    Maertens J; Lyon S
    Future Microbiol; 2013 Sep; 8(9):1063-5. PubMed ID: 24020734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antifungal resistant fungi].
    Maesaki S
    Nihon Rinsho; 2003 Mar; 61 Suppl 3():207-13. PubMed ID: 12717973
    [No Abstract]   [Full Text] [Related]  

  • 7. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.
    Pfaller MA; Diekema DJ
    J Clin Microbiol; 2004 Oct; 42(10):4419-31. PubMed ID: 15472288
    [No Abstract]   [Full Text] [Related]  

  • 8. The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus.
    Ostrosky-Zeichner L; Andes D
    J Infect Dis; 2017 Aug; 216(suppl_3):S452-S457. PubMed ID: 28911047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Echinocandin resistance in human pathogenic fungi.
    Munro CA
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):115-6. PubMed ID: 22339184
    [No Abstract]   [Full Text] [Related]  

  • 10. Antifungal Resistance: An Emerging Reality and A Global Challenge.
    Kontoyiannis DP
    J Infect Dis; 2017 Aug; 216(suppl_3):S431-S435. PubMed ID: 28911044
    [No Abstract]   [Full Text] [Related]  

  • 11. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on antifungal resistance in Aspergillus and Candida.
    Arendrup MC
    Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():42-8. PubMed ID: 24372701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates on Therapeutic Strategies Against Candida (and Aspergillus) Biofilm Related Infections.
    Muakkassa FK; Ghannoum M
    Adv Exp Med Biol; 2016; 931():95-103. PubMed ID: 27287466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The global problem of antifungal resistance: prevalence, mechanisms, and management.
    Perlin DS; Rautemaa-Richardson R; Alastruey-Izquierdo A
    Lancet Infect Dis; 2017 Dec; 17(12):e383-e392. PubMed ID: 28774698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Candida, aspergillus and company. Pathogenic fungi].
    Hof H
    Pharm Unserer Zeit; 2003; 32(2):96-103. PubMed ID: 12677961
    [No Abstract]   [Full Text] [Related]  

  • 16. Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.
    Espinel-Ingroff A; Arendrup M; Cantón E; Cordoba S; Dannaoui E; García-Rodríguez J; Gonzalez GM; Govender NP; Martin-Mazuelos E; Lackner M; Lass-Flörl C; Linares Sicilia MJ; Rodriguez-Iglesias MA; Pelaez T; Shields RK; Garcia-Effron G; Guinea J; Sanguinetti M; Turnidge J
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report from the European Congress of Clinical Microbiology and Infectious Diseases.
    Anttila VJ; Bryan J
    Future Microbiol; 2009 Sep; 4(7):783-7. PubMed ID: 19722833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspartic proteinases of Candida spp.: role in pathogenicity and antifungal resistance.
    Silva NC; Nery JM; Dias AL
    Mycoses; 2014 Jan; 57(1):1-11. PubMed ID: 23735296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging moulds: epidemiological trends and antifungal resistance.
    Miceli MH; Lee SA
    Mycoses; 2011 Nov; 54(6):e666-78. PubMed ID: 21672045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-drug resistant oral Candida species isolated from HIV-positive patients in South Africa and Cameroon.
    Dos Santos Abrantes PM; McArthur CP; Africa CW
    Diagn Microbiol Infect Dis; 2014 Jun; 79(2):222-7. PubMed ID: 24726686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.